Abstract
What are the aims appropriate for a science of clinical pharmacology and clinical trials: to test drugs for efficacy and safety in the clinic, to establish the optimal effectiveness and safety of drugs in patient care or both? Current designs of clinical trials test drugs for efficacy and safety in clinical settings-they do not address the clinicians problems adequately. Clinical trials better address the effectiveness of drugs in patient care with analyses to determine drug effects for each individual in the trial. We use current standards and designs for clinical trails supplemented to control random error effects for the individuals in the trials. Test-retest standard error of measurement can control random error effects for individuals. This allows individual clinical courses to be plotted with known precision and certainty. For individuals in a clinical trial the clinical course of surrogate outcome variables can be associated with long-term health outcomes in followup to develop clinical decision rules. Clinical courses on surrogate outcome variables during patient care can be interpreted using these clinical decision rules. In this Age of the Internet, Computers and Handhelds, electronic records and interpretations of clinical examinations and tests can be a part of decision making for every patient. We conclude that practical methods are available for making clinical trials more informative for clinical practice. This modification replaces “unsystematic clinical judgments” with statistically characterized data and interpretations for individuals available as care is delivered in the doctors office. An AD demonstration can be viewed at www.healthpragmatics.com.
Keywords: alzheimers disease, disease management, clinical trials, standard error of measurement, confidence interval of measurement, guidelines
Current Alzheimer Research
Title: Lessons from Darwin: Evolutionary Biologys Implications for Alzheimers Disease Research and Patient Care
Volume: 2 Issue: 3
Author(s): Robert E. Becker
Affiliation:
Keywords: alzheimers disease, disease management, clinical trials, standard error of measurement, confidence interval of measurement, guidelines
Abstract: What are the aims appropriate for a science of clinical pharmacology and clinical trials: to test drugs for efficacy and safety in the clinic, to establish the optimal effectiveness and safety of drugs in patient care or both? Current designs of clinical trials test drugs for efficacy and safety in clinical settings-they do not address the clinicians problems adequately. Clinical trials better address the effectiveness of drugs in patient care with analyses to determine drug effects for each individual in the trial. We use current standards and designs for clinical trails supplemented to control random error effects for the individuals in the trials. Test-retest standard error of measurement can control random error effects for individuals. This allows individual clinical courses to be plotted with known precision and certainty. For individuals in a clinical trial the clinical course of surrogate outcome variables can be associated with long-term health outcomes in followup to develop clinical decision rules. Clinical courses on surrogate outcome variables during patient care can be interpreted using these clinical decision rules. In this Age of the Internet, Computers and Handhelds, electronic records and interpretations of clinical examinations and tests can be a part of decision making for every patient. We conclude that practical methods are available for making clinical trials more informative for clinical practice. This modification replaces “unsystematic clinical judgments” with statistically characterized data and interpretations for individuals available as care is delivered in the doctors office. An AD demonstration can be viewed at www.healthpragmatics.com.
Export Options
About this article
Cite this article as:
Becker E. Robert, Lessons from Darwin: Evolutionary Biologys Implications for Alzheimers Disease Research and Patient Care, Current Alzheimer Research 2005; 2 (3) . https://dx.doi.org/10.2174/1567205054367856
DOI https://dx.doi.org/10.2174/1567205054367856 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Synthesis and Characterization of Carboxymethyl Chitosan Hydrogel: Application as pH-Sensitive Delivery for Nateglinide
Current Drug Delivery Recent Clinical Aspects of Eating Disorders
Reviews on Recent Clinical Trials The Crosstalk Between Insulin and Renin-Angiotensin-Aldosterone Signaling Systems and its Effect on Glucose Metabolism and Diabetes Prevention
Current Vascular Pharmacology Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Spoligotyping for Identification of Pulmonary Tuberculosis with Type 2 Diabetes Mellitus Profiles in Warangal, T.S.
Anti-Infective Agents Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews Visual and Quantitative Assessment of COVID-19 Pneumonia on Chest CT: The Relationship with Disease Severity and Clinical Findings
Current Medical Imaging Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Eye Disorders in Diabetes: Potential Drug Targets
Infectious Disorders - Drug Targets Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews ATP-Binding Cassette Transporters A1 and G1, HDL Metabolism, Cholesterol Efflux, and Inflammation: Important Targets for the Treatment of Atherosclerosis
Current Drug Targets Effect of GLP-1 Based Therapies on Diabetic Dyslipidemia
Current Diabetes Reviews Thrombocytopenia in HIV Infection: Impairment of Platelet Formation and Loss Correlates with Increased c-Mpl and Ligand Thrombopoietin Expression
Current HIV Research Insights into the Platelet Releasate
Current Pharmaceutical Design The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad
Current Vascular Pharmacology D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry